Systemic Neoadjuvant and adjuvant Control by Precision medicine in rectal cancer (SYNCOPE) – approach on high-risk group to reduce metastases

Status

Not yet recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-517149-15-00

Enrollment

100

Registered

2024-09-24

Start date

Unknown

Completion date

Unknown

Last updated

2024-09-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rectal cancer

Brief summary

Recurrence-free survival at 3 (and 5) years at intention-to-treat analysis

Interventions

DRUGCapecitabine Orion 150 mg kalvopäällysteiset tabletit

DRUGOxaliplatin Accord 5 mg/ml

DRUGinfuusiokonsentraatti

DRUGliuosta varten.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Recurrence-free survival at 3 (and 5) years at intention-to-treat analysis	—

Countries

Finland

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026